Literature DB >> 24472366

Model-based angiogenic inhibition of tumor growth using modern robust control method.

Levente Kovács1, Annamária Szeles2, Johanna Sápi3, Dániel A Drexler2, Imre Rudas3, István Harmati2, Zoltán Sápi4.   

Abstract

Cancer is one of the most destructive and lethal illnesses of the modern civilization. In the last decades, clinical cancer research shifted toward molecular targeted therapies which have limited side effects in comparison to conventional chemotherapy and radiation therapy. Antiangiogenic therapy is one of the most promising cancer treatment methods. The dynamical model for tumor growth under angiogenic stimulator/inhibitor control was posed by Hahnfeldt et al. in 1999; it was investigated and partly modified many times. In this paper, a modified version of the originally published model is used to describe a continuous infusion therapy. In order to generalize individualized therapies a robust control method is proposed using H(∞) methodology. Uncertainty weighting functions are determined based on the real pathophysiological case and simulations are performed on different tumor volumes to demonstrate the robustness of the proposed method.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Antiangiogenic therapy; H(∞) method; Robust control; Uncertainty

Mesh:

Substances:

Year:  2014        PMID: 24472366     DOI: 10.1016/j.cmpb.2014.01.002

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  3 in total

1.  Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy.

Authors:  Johanna Sápi; Levente Kovács; Dániel András Drexler; Pál Kocsis; Dávid Gajári; Zoltán Sápi
Journal:  PLoS One       Date:  2015-11-05       Impact factor: 3.240

2.  Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data.

Authors:  Katerina D Argyri; Dimitra D Dionysiou; Fay D Misichroni; Georgios S Stamatakos
Journal:  Biol Direct       Date:  2016-03-22       Impact factor: 4.540

3.  A Minimal PKPD Interaction Model for Evaluating Synergy Effects of Combined NSCLC Therapies.

Authors:  Clara Mihaela Ionescu; Maria Ghita; Dana Copot; Eric Derom; Dirk Verellen
Journal:  J Clin Med       Date:  2020-06-12       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.